论文部分内容阅读
《中国肿瘤临床》2015年第19期“专家论坛”中,来自于中国医学科学院肿瘤医院肿瘤内科李峻岭教授,结合近期关于非小细胞肺癌(NSCLC)的一系列临床研究结果,从NSCLC的一线治疗、维持治疗、后线治疗等方面对晚期NSCLC的临床治疗策略进行论述。新的靶向治疗药物和免疫治疗药物的出现,为肺癌(尤其是NSCLC)的治疗提供了更多选择,但同时也带来了更大的挑战,如何选择合适的治疗策略,以期最大程度延长患者生存期、提高
Professor Li Junling, from Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, combined with the recent results of a series of clinical studies on non-small cell lung cancer (NSCLC), from “NSFLC” First-line treatment, maintenance treatment, after-treatment and so on the clinical treatment of advanced NSCLC strategy. The emergence of new targeted therapies and immunotherapeutics offers more options for the treatment of lung cancers, especially NSCLC, but also presents greater challenges and how to choose the appropriate treatment strategy with a view to maximizing Patient survival increased